Compare NYXH & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYXH | SABA |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.6M | 223.9M |
| IPO Year | 2021 | 1994 |
| Metric | NYXH | SABA |
|---|---|---|
| Price | $3.47 | $8.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | 55.5K | ★ 127.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.32 | N/A |
| Revenue Next Year | $241.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.65 | $7.72 |
| 52 Week High | $11.87 | $9.46 |
| Indicator | NYXH | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 31.75 | 52.68 |
| Support Level | N/A | $7.97 |
| Resistance Level | $5.02 | $8.27 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 6.18 | 60.10 |
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.